Quick Answer
C4 Therapeutics, Inc. reported Net Income Loss of -$104.99 million for the year ending 2025.
- C4 Therapeutics, Inc. showed an increase of +0.3% in Net Income Loss from 2024 to 2025.
- This data is from C4 Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: -$10.09 million | Q1 2020: -$11.91 million | Q2 2020: -$10.79 million | Q3 2020: -$21.84 million | Q1 2021: -$20.97 million | Q2 2021: -$22.58 million | Q3 2021: -$24.68 million | Q1 2022: -$31.62 million | Q2 2022: -$27.41 million | Q3 2022: -$31.96 million | Q1 2023: -$34.78 million | Q2 2023: -$35.92 million | Q3 2023: -$27.04 million | Q1 2024: -$28.36 million | Q2 2024: -$17.72 million | Q3 2024: -$24.67 million | Q1 2025: -$26.32 million | Q2 2025: -$26.02 million | Q3 2025: -$32.17 million.
- Over the full 7 years of available data (2019 to 2025), C4 Therapeutics, Inc.'s Net Income Loss has declined by 207.9%.
- Historical annual values: Fiscal year 2025: -$104.99 million | Fiscal year 2024: -$105.32 million | Fiscal year 2023: -$132.49 million | Fiscal year 2022: -$128.18 million | Fiscal year 2021: -$83.89 million | Fiscal year 2020: -$66.34 million | Fiscal year 2019: -$34.10 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: